Discounted Cash Flow

Omega Healthcare Investors Inc. REIT

OHI · Based on 10 years of SEC filings · Converted from GBP to USD

—

Cash flow predictability 79/100 (stable) — FCF YoY std dev 14%, net income 74% (full history)

▲ Accelerating sales growth

Sales growth has accelerated: 8.1% (2023) → 10.7% (2024) → 13.2% (2025). Revenue growth has been accelerating in recent years and is now 13.2% — rapidly accelerating growth may be difficult to sustain at this pace, or the DCF (based on historical averages) may understate future momentum.

Average annual growth rates

Metric	10-Year	5-Year	3-Year
Sales	—	—	—
Free Cash Flow	—	—	—
Average (FCF & NI)	—	—	—
Net Income	—	—	—
Dividends	—	—	—

Average annual growth is the mean year-over-year change across each period.

Endpoint CAGR (better for long term trend)

Metric	10-Year	5-Year	3-Year
Sales	—	—	—
Free Cash Flow	—	—	—
Average (FCF & NI)	—	—	—
Net Income	—	—	—

Endpoint CAGR is the compound annual rate from the first to last year in each period.

Projections use average year-over-year growth. Change this in Settings.

Projected growth rate

—

Free cash flow growth —

10-year: — 5-year: — 3-year: —

Averaged growth (FCF & NI) —

10-year: — 5-year: — 3-year: —

Net income growth —

10-year: — 5-year: — 3-year: —

Sales growth (not added to calculations) —

10-year: — 5-year: — 3-year: —

Click a greyed-out slider to switch metrics. Slide between the 10-year, 5-year, and 3-year historic growth rates for FCF, net income, or their average.

Or enter your own rate

Inflation rate (used with B/E only)

Historical inputs (10 fiscal years)

YEAR	Sales	Net Income	Free Cash Flow	Net Margin	EPS (diluted)
2016	$1.2b	$495.0m	$843.9m	40.7%	$1.91
2017	$1.2b (0.8%)	$135.6m (-72.6%)	$780.6m (-7.5%)	11.1% (-72.8%)	$0.51 (-73.3%)
2018	$1.2b (-2.9%)	$380.4m (180.4%)	$674.6m (-13.6%)	31.9% (188.9%)	$1.41 (176.5%)
2019	$1.3b (5.3%)	$2 (-100.0%)	$748.0m (10.9%)	0.0% (-100.0%)	$1.60 (13.5%)
2020	$1.2b (-3.9%)	$215.2m (10083987241.8%)	$956.7m (27.9%)	17.9% (10495864292.7%)	$0.70 (-56.2%)
2021	$1.4b (19.1%)	$562.9m (161.6%)	$847.0m (-11.5%)	39.2% (119.6%)	$1.76 (151.4%)
2022	$1.2b (-17.4%)	$576.7m (2.4%)	$845.2m (-0.2%)	48.6% (24.0%)	$1.81 (2.8%)
2023	$1.3b (8.1%)	$327.1m (-43.3%)	$834.4m (-1.3%)	25.5% (-47.5%)	$1.01 (-44.2%)
2024	$1.4b (10.7%)	$548.9m (67.8%)	$1.0b (21.3%)	38.6% (51.6%)	$1.57 (55.4%)
2025	$1.6b (13.2%)	$797.2m (45.2%)	$1.2b (17.2%)	49.6% (28.3%)	$1.96 (24.8%)

Base FCF: — (latest fiscal year)

Discount rate: %

Terminal growth: —

Projection period: — years

Alt A decline yrs:

Alt B total yrs:

SEC filings report in GBP. Values above are converted to USD for comparison with the US-listed share price.

Values abbreviated: b = billions, m = millions, k = thousands.

Projected cash flows

Year	Projected cash flow	Discount Factor	Present Value

PV of projected FCF: —

Terminal FCF: —

Terminal value: —

PV of terminal value: —

Enterprise value (DCF): —

Current price: —

Alternative DCF Models

Model	Fair Value	Upside	PV(FCFs)	PV(Terminal)	Total Years
Standard (10yr→TV) ⓘ	—	—	—	—	10 + TV
Alt A (Gradual Decline) ⓘ	—	—	—	—	—
Alt B (30yr Hard Stop) ⓘ	—	—	—	N/A	—

This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.

+ 10YR Financials Balance Sheet (10YR) Cash Flow (10YR) DCF Model